HK Stock Market Move | True Health Medical (02697) rose over 6% as it partners with General Technology Liaoning Pharmaceutical to jointly expand the Northeast minimally invasive tumor treatment market, accelerating the formation of the company's business closed loop.

Zhen Health Medical (02697) rose more than 6%; as of the time of writing, it is up 5.09%, trading at HKD 692, with a transaction volume of HKD 11.297 million. On the news front, on August 25, Zhen Health Medical announced a voluntary disclosure stating that it signed a strategic cooperation framework agreement with General Technology Liaoning Pharmaceutical in Shenyang on August 22. Both parties will focus on the three northeastern provinces, collaborating on the construction of a minimally invasive tumor diagnosis and treatment system, compliant operation of equipment, and enhancement of specialized capabilities. They will employ models such as joint construction of specialties, equipment technology services, and operational leasing to promote the standardization of minimally invasive interventional techniques for tumors. Zhen Health Medical's national expansion is completing a strategic depth advancement across thousands of kilometers, from the Guangdong-Hong Kong-Macao Greater Bay Area to the old industrial base in Northeast China, from the Hengqin Guangdong-Macao Deep Cooperation Zone to the central enterprise provincial platform. It is worth mentioning that by June 1, 2026, the company's products have entered nearly a hundred medical institutions nationwide, with over 7,200 surgeries completed and a technical success rate of 100%; six devices are to be delivered in 2025, with revenue increasing from RMB 1.791 million in 2024 to RMB 12.178 million, representing a year-on-year growth of approximately 5.8 times, and a gross margin of 76.3%. From obtaining certifications to equipment installation and then to the repurchase of consumables, Zhen Health Medical's business cycle is accelerating towards formation.